- Home
- LGMK vs AWH Comparison
LGMK vs AWH Comparison
Compare LGMK & AWH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGMK
- AWH
- Stock Information
- Founded
- LGMK 2011
- AWH 1993
- Country
- LGMK United States
- AWH United States
- Employees
- LGMK N/A
- AWH N/A
- Industry
- LGMK Industrial Specialties
- AWH Medical/Dental Instruments
- Sector
- LGMK Health Care
- AWH Health Care
- Exchange
- LGMK Nasdaq
- AWH Nasdaq
- Market Cap
- LGMK 1.3M
- AWH 1.6M
- IPO Year
- LGMK N/A
- AWH N/A
- Fundamental
- Price
- LGMK $0.02
- AWH $0.11
- Analyst Decision
- LGMK
- AWH Buy
- Analyst Count
- LGMK 0
- AWH 2
- Target Price
- LGMK N/A
- AWH $4.40
- AVG Volume (30 Days)
- LGMK 36.8M
- AWH 13.0M
- Earning Date
- LGMK 05-14-2025
- AWH 03-27-2025
- Dividend Yield
- LGMK N/A
- AWH N/A
- EPS Growth
- LGMK N/A
- AWH N/A
- EPS
- LGMK N/A
- AWH N/A
- Revenue
- LGMK $9,901,987.00
- AWH $9,182,000.00
- Revenue This Year
- LGMK $1.54
- AWH $11.87
- Revenue Next Year
- LGMK N/A
- AWH $79.10
- P/E Ratio
- LGMK N/A
- AWH N/A
- Revenue Growth
- LGMK 4.43
- AWH 0.31
- 52 Week Low
- LGMK $0.02
- AWH $0.08
- 52 Week High
- LGMK $25.38
- AWH $3.63
- Technical
- Relative Strength Index (RSI)
- LGMK 11.89
- AWH 33.87
- Support Level
- LGMK $0.02
- AWH $0.12
- Resistance Level
- LGMK $0.11
- AWH $0.36
- Average True Range (ATR)
- LGMK 0.02
- AWH 0.01
- MACD
- LGMK 0.02
- AWH 0.01
- Stochastic Oscillator
- LGMK 1.05
- AWH 37.14
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.